Relationship between benralizumab exposure and asthma exacerbation rate for patients with severe asthma Source: International Congress 2017 – Asthma: mechanisms and treatment Year: 2017
The influence of smoking on the treatment response in patients with asthma Source: Annual Congress 2007 - PG15 - Difficult-to-treat asthma: dealing with smoker patients Year: 2007
Omalizumab (Xolair®) reduces exacerbations in patients with moderate-to-severe persistent allergic asthma independent of former smoking status Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008
Age is a predictor of efficacy of monoclonal antibodies in allergic severe asthma Source: International Congress 2019 – COPD, asthma and rhinitis: from cellular mechanisms to patients’ clinical responses Year: 2019
Omalizumab, a recombinant humanized monoclonal anti-IgE antibody, decreases the risk of serious asthma exacerbations requiring hospitalization in patients with moderate-to-severe allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001
Is omalizumab response influenced by passive smoking in severe asthma? Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018
The impact of smoking cessation on respiratory symptoms in patients with COPD Source: Eur Respir J 2005; 26: Suppl. 49, 391s Year: 2005
The effect of passive smoking on severity of children asthma Source: Eur Respir J 2001; 18: Suppl. 33, 453s Year: 2001
Effects of exposure to parental smoking on pulmonary function and symptoms in children with asthma Source: Annual Congress 2011 - Coping and lifestyle in childhood asthma Year: 2011
Real-life effectiveness of anti-IL-5(-receptor) antibody treatment in patients with severe eosinophilic asthma Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019
Monoclonal antibody treatments for paediatric severe asthma–outcomes, attitudes and adherence Source: Virtual Congress 2021 – Paediatric allergic asthma: novel therapeutics and monitoring approaches Year: 2021
The Dutch hypothesis, implications for treatment of chronic obstructive pulmonary disease and asthma in a biomarker, monoclonal antibody world. Experience with IgE and omalizumab in a small pulmonary practice Source: Annual Congress 2011 - Airways disease comorbidities and general aspects Year: 2011
Impact of smoking in patients with and without history of asthma Source: Annual Congress 2011 - Asthma: a heterogeneous disease Year: 2011
Recommendations for smoking cessation treatment in respiratory patients Source: Annual Congress 2007 - PG15 - Difficult-to-treat asthma: dealing with smoker patients Year: 2007
Quantification of smokers and smoking status among COPD patients, hospitalized for an exacerbation Source: Annual Congress 2011 - Challenges in rehabilitation: some old dilemmas revisited with some solutions? Year: 2011
Long-term treatment with monoclonal antibodies anti-IgE in severe asthma: Follow-up of ten patients Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E Year: 2011
Long-term asthma control with omalizumab, an anti-IgE monoclonal antibody, in patients with severe allergic asthma Source: Eur Respir J 2005; 26: Suppl. 49, 47s Year: 2005
Smoking cessation among COPD and asthma patients: burden vs. motivation Source: International Congress 2018 – Tobacco use and cessation interventions in patients with respiratory, cardiovascular and mental health problems and other populations Year: 2018
Smoking cessation in COPD patients (with comorbidities) Source: International Congress 2017 – PG14 Smoking cessation in patients with respiratory diseases Year: 2017
Asthma patients adjust their maintenance treatment late in response to worsening asthma symptoms Source: Eur Respir J 2005; 26: Suppl. 49, 7s Year: 2005